ICSI (280 552), frozen embryo replacements (FER, 97 120), egg donation (ED, 13 609), in vitro maturation (IVM, 562), preimplantation genetic diagnosis/screening (PGD/PGS, 2875) and frozen oocyte replacements (FOR, 4080). Overall, this represents a 7.9% increase in the activity since 2007, which is mainly related to an increase in cycles from almost all registers and only partially to the new countries entering EIM (Estonia, Kazakhstan, Moldova and Romania, 5480 cycles in total). European data on intrauterine insemination using husband/partner's (IUI-H) and donor (IUI-D) semen were reported from 27 and 21 countries, respectively. A total of 144 509 IUI-H (+1.5%) and 24 960 IUI-D (24.3%) cycles were included.
Introduction
This report is the 12th annual European Society of Human Reproduction and Embryology (ESHRE) publication on European data on assisted reproductive technology (ART). The 11 previous reports, also published in Human Reproduction (ESHRE, 2001a (ESHRE, ,b, 2002 (ESHRE, , 2005 (ESHRE, , 2006 (ESHRE, , 2007 (ESHRE, , 2008 Nyboe Andersen et al., 2009; de Mouzon et al., 2010; de Mouzon et al., 2012) , covered treatment cycles from 1997 to 2007. As in the last report, the printed version contains the four most significant tables. Additional tables are available online, making the whole report consistent with those from previous years. In the published report, these online tables will be referred to as 'Supplementary data, Tables SI -SXVIII'. The main results of this report were presented at the annual ESHRE congress in Stockholm, July 2011.
Materials and Methods

Data collection
Data on ART have been collected from 36 European countries, covering IVF, ICSI, frozen embryo replacement (FER), egg donation (ED), in vitro maturation (IVM), pooled data on preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) and frozen oocyte replacements (FOR) . In addition to ART, data on intrauterine inseminations using husband/partner's semen (IUI-H; 27 countries, 5 more than in 2007) and donor semen (IUI-D; 21 countries, 3 more than in 2007) were also included. The report includes treatments started between the 1st of January and the 31st of December 2008. Data on pregnancy outcomes are derived from the follow-up of the cohort treated during this time period.
The method of reporting used for 2008 data is similar to that used for the previous year, making all tables comparable. However, the Consortium agreed to add an optional module for data collection on cycles performed for cross-border patients. As in previous years, data were directly entered in ESHRE's computer system by each country co-ordinator, through software developed by ESHRE. Data analysis was performed in the ESHRE central office by V. Goossens.
As is evident in the tables and underlined in the footnotes, registers from a number of countries have been unable to provide some of the data requested. Therefore, each total (in terms of numbers and percentages) refers to those countries where all data have been reported. Some countries did not report the number of initiated cycles; several countries had a high percentage of pregnancies lost to follow-up. Therefore, some of the best indicators in reporting outcomes (clinical pregnancies and deliveries per initiated cycles) cannot be reported correctly and caution should be exercised in comparing outcomes among countries.
Results
Participation
The present report includes data from 36 (Table I ) out of 47 European countries. Since the first report for 1997, the number of countries contributing data has doubled. Compared with 2007, four new countries (Estonia, Kazakhstan, Moldova and Romania) entered the Consortium but Cyprus was not able to send data. The proportion of clinics reporting data (listed in the Supplementary data) was 84. 5% (86% in 2007) . In 19 countries (one more compared with 2007) the coverage reached 100%. Switzerland was able to report data from all but a single centre. Participation was limited (25 -50%) in Albania, Lithuania, Romania and Serbia and very low (≤25% of clinics) in Greece (12%), Kazakhstan (17%), Bosnia (20%) and Latvia (25%). Among the most populous countries, the coverage was 100% (similar to 2007) in Germany, Italy, UK and Turkey, 95% in France (100% in 2007) , 74% in Russia (79% in 2007) but only 50% in Spain (61% in 2007) .
Reporting methods and size of the clinics
Among the 19 countries with complete reporting (Supplementary data, Table SII), the register was compulsory for 14 (10 held by a National Health Authority and 4 by a Medical Organization) and voluntary for 5 (4 held by a Medical Organization and 1 by personal initiative). Only seven registers were based on individual forms, i.e. cycle-by-cycle data.
Among the 17 countries with partial coverage, 4 were compulsory (2 held by a National Health Authority and 2 by a Medical Organization) and 13 voluntary and only 3 used individual forms.
The distribution of clinics according to the number of cycles varied considerably among the countries (Supplementary data, Table SIII ). For instance, small clinics, providing fewer than 100 cycles annually, accounted for 88 out of 207 clinics in Italy (42.5%) and 4 out of 10 (40%) in Bulgaria, whereas large clinics performing .1000 cycles a year, constituted 12/18 (66.7%) in Belgium, 2/3 (66.7%) in Slovenia and 8/13 (61.5%) in the Netherlands. The only clinic reporting from Kazakhstan performed over 1000 cycles.
Number of treatment cycles per technique and availability
In total, 532 260 cycles were reported (Table I) , 39 076 more than in 2007 (+7.9%). Among the 405 091 fresh cycles, 124 539 were IVF and 280 552 were ICSI. The proportion of ICSI thus continued to increase, reaching 69% of fresh ART cycles (68% in 2007). In Turkey, 98% were ICSI cycles; in two countries (Bosnia and the Czech Republic) IVF and ICSI was most often combined.
FER was performed in 32 countries, reporting 97 120 cycles (+5975 compared with 2007). Overall, the proportion in comparison with 'fresh' cycles was 24.0% (the same as in 2007) but in some countries the proportion was .50% (Switzerland, Finland, Latvia, Iceland and Belgium) .
The number of ED cycles, reported by 24 countries, was 13 609 (22122 compared with 2007). Table II shows the pregnancy and delivery rates per aspiration for IVF, ICSI and FER. One country (Turkey) could not provide pregnancies and deliveries subdivided per technique (IVF and ICSI), one country (Austria) only provided data on pregnancy/transfers and no data on deliveries, and three countries (Czech Republic, Latvia and Poland) did not provide data on deliveries. Thus, the mean pregnancy and delivery rates were computed for countries providing the relevant information. There were significant national variations in clinical outcomes. On average, the pregnancy rates were 28.5% (20.6% compared with Numbers of documented pregnancy losses (spontaneous abortions) were reported by 33 countries for IVF and ICSI and by 28 countries for FER (Supplementary data, Tables SXII and SXIII) . In these countries, the rates varied from 10 to 35% for fresh cycles (a mean of 18.5%) and from 11 to 37% for FER (a mean of 24%). The figures may be underestimated because of pregnancies lost to followup. In the 16 countries with complete follow-up, the figures were 20.6% for fresh cycles (5741/27869) and 27% for FER (1643/5986).
Pregnancies and deliveries after treatment
In total, 107 383 infants were recorded as having been born as a consequence of IVF, ICSI and FER in the 33 countries where the reporting included newborns (+10 693 compared with 2007). In the countries with 100% coverage with relevant data, the percentage of babies conceived through ART on the national births varied from 0.5% in Turkey to 4.6% in Denmark. More details are provided in Supplementary data, Table SI, showing that the percentage of ART babies was above 3.0%, in most of the Nordic countries, and between 1.3 and 1.9% in some of the largest European countries (Germany, UK and Italy).
In Finland, Iceland and Switzerland, one out of three ART infants was born after FER.
ED was reported by 24 countries (Supplementary data, Table SVII ). In most of the countries where data were not reported, the technique was illegal. In total, 5213 clinical pregnancies resulted from 10 601 embryo transfers with pregnancy rates of 43.2% per transfer versus 46.2% in 2007. The mean delivery rate was 30.8% per transfer (n ¼ 3243) in the 22 countries reporting deliveries.
Age distribution
The age distribution of women treated with IVF and ICSI varied across countries (Supplementary data, Tables SVIII and SIX). The highest percentages of women aged 40 years or more were found in Greece and Italy, whereas the highest percentages of women aged 34 years or less were found in countries from East Europe. As expected, the pregnancy rates associated with IVF and ICSI decreased with advancing age. The same trend was seen for delivery rates. FER cycles (Supplementary data, Table SX) included a relatively higher percentage of young women (≤34 years) and, as in fresh cycles, pregnancies and deliveries rates decreased with age. In ED cycles (Supplementary data, Table SXI), the age of the recipient was 40 years or more in 54.4% of cases on average, and few countries reported a figure less than Treatment cycles in IVF and ICSI should refer to initiated cycles. For Austria and Germany, the total number of cycles is higher than the sum of cycles because they report the number of initiated cycles for fresh cycles only globally. Therefore, in the overall calculation, the total number of cycles is not equal to the sum of cycles per technique. For Belgium, France, Germany, Iceland, Kazakhstan, Lithuania and Turkey treatment cycles refer to aspirations, for Austria they refer to transfers. ART infants also include ED. For IVF and ICSI there were for France, Greece, Poland, Romania and Russia respectively 106, 6, 39, 31 and 345 deliveries with unknown outcome. These were accepted as singletons to calculate the ART infants. For FER there were for Greece, Poland, Portugal, Russia and Switzerland respectively 1, 7, 1, 3 and 3 deliveries with unknown outcome. These were accepted as singletons to calculate the ART infants. For ED there were for Russia 6 deliveries with unknown outcome. These were accepted as singletons to calculate the ART infants. For PGD there were for Finland and Russia respectively 3 and 1 deliveries with unknown outcome. These were accepted as singletons to calculate the ART infants. For Lithuania % deliveries removed.
40% : Belgium (39.7%), Bulgaria (39.3%), Denmark (23.2%), Estonia (33.3%) and Sweden (8.1%). Pregnancy and delivery rates in oocyte recipients were comparable across different age groups. 
Number of embryos transferred and multiple births
Perinatal risks and fetal reductions
Supplementary data, Table SXIV shows the risk of preterm deliveries according to the number of newborns. Data were available from 17 countries. These show that the risk of extreme preterm birth (gestational week 20-27) increased from 0.8% for a singleton delivery to 3.2% for twins and 5.9% for triplets. The same trend was noted for a singleton delivery, twins and triplets for very preterm (28 -32 weeks) births, from 1.9% to 10.0% and 32.4%, respectively, and for preterm (33 -36 weeks) births, from 8.5% to 41.5% and 54.4%, respectively.
Ovarian hyperstimulation syndrome (OHSS) was reported in 30 of the 36 countries (Supplementary data, Table SXV ). In total, 2947 cases of OHSS were recorded, corresponding to a risk of OHSS of 1.0% of all stimulated cycles in the countries reporting the data. The table also includes other adverse outcomes, such as bleeding (652) 
In vitro maturation
IVM was recorded in 12 countries (Table I) 
Frozen oocyte replacement
FOR was recorded by the same nine countries of 2007 report, with a total of 4080 thaws, 3359 transfers, 556 pregnancies and 358 deliveries. The majority (80%) was performed in Italy.
Intrauterine inseminations
Table IV provides data on IUI-H (reported by 27 countries) and IUI-D (reported by 21 countries).
For IUI-H, 144 509 cycles were reported (+1900); the main contributors being Denmark, France, Italy, Spain and the UK. Among the countries reporting deliveries, the mean delivery rate was 9.1% per cycle (20.1%) with 10.6% of deliveries being twin (20.8%) and 0.7% triplet deliveries (+0.1%).
For IUI-D, 24 960 cycles were reported (21128), the main contributors being Denmark, France, Spain and UK. The delivery rate was 13.8% per cycle (equal to 2007), with multiple delivery rates of 9.4% for twins and 0.3% for triplets. Table SXVII ). The delivery rate associated with IUI-H declined with age (10.5% below 40 versus 5.5% above), and the multiple delivery rate decreased slightly from 11.0 to 8.8% for twins, and from 0.8 to 0.0% for triplets. Similar findings were seen in IUI-D, where delivery rates decreased from 13.5 to 6.6%, twin deliveries from 9.5 to 3.7% and triplets from 0.3 to 0.0%.
Data are presented on IUI outcomes in women below 40 years (upper panel) and 40 years or more (lower panel), both for IUI-H (Supplementary data, Table SXVI) and IUI-D (Supplementary data,
Cumulative delivery rates
Supplementary data, Table SXVIII gives an estimate of the cumulative delivery rates per initiated stimulated cycle, presented as the sum of fresh and FER pregnancies obtained during the same year. While not a true cumulative delivery rate per couple per cycle, the calculation shows that the delivery rate (fresh versus cumulative) can increase in countries reporting the relevant data. Overall, the increase was from 19.4 to 22.5% (+16%) but in some countries (Switzerland, Finland, Sweden and Belgium) the increment was more substantial (+58%, +54%, +35%, +33%, respectively). Additionally, Supplementary data, Table SXVIII shows the rate of multiple deliveries after the 'fresh' cycles and the FER combined. The overall multiple delivery rate was particularly low in Sweden and Finland: 6.6% and 9.7%, respectively, with relatively high cumulative delivery rates (29.4% and 30.5%)
Cross-border reproductive care
Seven countries reported data on cross-border patients: Iceland, Kazakhstan, Latvia, Macedonia, Poland, Slovenia and Spain. They reported 2512 ART cycles, of which 1040 were performed for egg donation, 58 for semen donation, 32 for PGD and the other cycles for IVF/ICSI with the couple's own gametes. Additionally 86 IUI cycles with sperm donation were reported. Overall, they represent 4.6% of all cycles performed in those countries but in Latvia they made up 70% (238/340) of all ART cycles. The main countries of origin of the patients and the reasons for cross-border care were not sufficiently detailed to allow any meaningful conclusions to be drawn.
Discussion
The present report is the 12th, consecutive annual European report on ART data. Together the 12 reports cover treatment cycles from 1997 to 2008. As shown in the tables, the method of reporting varies among countries and registers from a number of countries have been unable to provide some of the data. In addition, some countries may still not have implemented ( Overall, the number of reported cycles increased by 7.9% since 2007(+39 076), reaching a total of 532 260. Elsewhere in the world in 2008, 148 055 cycles were reported from the USA (CDC, 2010) and 61 929 cycles from Australia and New Zealand (AIHW, 2010) .
After the sharp decline in the number of cycles in Germany between 2003 and 2005 (from 102 000 to 53 000) related to the reduction in the re-imbursement for ART, a slow but gradual increase is evident with the number of cycles rising to 69 902 in 2008.
As shown in Table I , the average number of treatment cycles per million inhabitants was 947 but data are suggestive of huge differences in access, with the highest figures from Belgium (2687) and Denmark (2450) and the lowest from Moldova (150). A better way to define the availability of ART is to use women of reproductive age (15 -45 years as the denominator, which eliminates the impact of age differences across the countries (Table I) . Again, there were striking differences in access, ranging from 589 cycles in Moldova to 13 069 in Belgium and 12 712 in Denmark. Countries able to provide over 8000 cycles per million women of reproductive age and over 1700 cycles per million inhabitants were the Czech Republic, Estonia, Finland, Iceland, Norway and Slovenia. Overall, the highest availability was reported by Nordic countries. Finally, the percentage of newborns conceived through ART varied from 0.5% in Turkey to 4.6% in Denmark (Supplementary data, Table SI ). The proportion of ICSI versus conventional IVF procedures continues to increase (49% in 2004, 66.5% in 2006, 68% in 2007 and 69% in 2008) . As recently reviewed, the trend towards increased use of ICSI has been observed throughout the world (Nyboe Andersen et al., 2008; ICMART, 2009) . In Australia and New Zealand, 63.2% of all cycles used ICSI in 2008 and in the USA the corresponding figure was 64.3%, reflecting a uniform trend in those three regions. However, Table I demonstrates a marked variation in the relative proportions of IVF and ICSI within Europe, with Turkey being the most frequent user of ICSI (98%) and Romania the least (17%). The difference seems to have a geographic distribution: in several countries from Northern and Eastern Europe (Denmark, Finland, Iceland, Ireland, The Netherlands, UK, Lithuania, Kazakhstan, Romania, Russia and Serbia) IVF remains the dominant technology. In contrast, in most countries from Western and Central Europe (Germany, Italy, Spain, Austria and Switzerland) ICSI was used in .75% of cases. The marked increase in the use of ICSI in the world cannot be explained by a similar increase in male infertility but rather by a more liberal use of this technique in cases with mixed infertility, unexplained infertility, mild male factor infertility and fertilization failures (Jain and Gupta, 2007; Nyboe Andersen et al., 2008) . This is, however, unlikely to fully account for the observed differences, which can only be explained by differences in professional strategy and clinical decision-making. In the USA, 52.9% of ICSI cycles were performed in couples without a diagnosis of male factor infertility (CDC, 2010) .
Overall, in 2008, the number of transfers with three or more embryos (24.4%) was lower compared with 2007 (25.2%) but still higher than in 2006 (20.6%). The mean percentage of SETs increased from 21.4 to 22.4%, a figure similar to 2006. The proportion of DET remained stable compared with 2007 (53.2% versus 53.4%) but was lower than in 2006 (57.3%). The trend observed in previous years towards the transfer of fewer embryos seems to have reached a plateau; however, these findings may be mostly explained by the inclusion, during the last years, of data from new countries (Turkey, with a large number of treatment cycles, but also Romania, Moldova and Lithuania) where .50% of transfers were performed with three or more embryos. To have a clearer view of the overall trend over time, the countries transferring four or more embryos in .10% of the cycles decreased from 7 countries in 2007 (Bosnia, Bulgaria, Greece, Macedonia, Montenegro, Turkey and Ukraine) to only two in 2008 (Bulgaria and Lithuania). Conversely, a constant increase in the number of SETs was observed in Belgium (50.4%, +0.2%), Bosnia (52.0%, +2.4%), Finland (62.1%, +4.3%), Iceland (48.5%, +1.9%) and Slovenia (30.4%, +2.8%). A stable, high proportion of SETs was found in Sweden (69.5%), Norway (52.9%) and Denmark (39.6%). The EIM reports are unable to discriminate between the elective SET (eSET) versus the SET in general but the rise in the number of transfers of one embryo seen in the last years is undoubtedly related to a rise in eSET. Despite fluctuations, the overall trend towards transferring fewer embryos seen over the last 10 years seems to continue. However, many differences in embryo transfer policy continue to exist across countries.
Similar observations can be made for the multiple delivery rates. In 2008, the multiple delivery rates (twins + triplets) were marginally lower compared with 2007 (21.7% versus 22.3%) but slightly higher than in 2006 (20.8%). The remarkable reduction in triplet deliveries observed from early years (3.6% in 1997 and 1.0% in 2008) persists but no real reductions are seen since 2005. As is clear from Table III , major differences in triplet and twins rates are still evident across countries. Some countries registered a triplet delivery rate .2.5% (Albania, Italy, Lithuania, Macedonia, Serbia and Turkey) while other countries were able to maintain the twin + triplets deliveries at ,10% (Bosnia, Finland and Sweden).
We have included data describing preterm birth rates according to the number of fetuses of the pregnancy (Supplementary data, Table  SXIV ). It was completed by 17 countries. The risk of extreme preterm birth (,28 weeks) was increased 4-fold for twins and 7-fold for triplets. The risk of very preterm (28-32 weeks) birth is increased almost 6-fold for twins and 18-fold for triplets.
Fetal reductions are almost always performed in triplet or higher order gestations. Thus, when analysing the range of triplet delivery rates in different countries, the number of fetal reductions should also be considered. A total of 394 procedures were reported (30 more than in 2007). However, the number is likely to be an underestimate since several countries, including large countries such as France, Germany and Turkey, did not report on this intervention. Without fetal reductions, the proportion of triplet deliveries would have been much higher than the number of recorded triplet deliveries (782 in total).
Finally, the delivery rates per aspiration remained relatively stable for IVF (21.2%) and ICSI (20.4%) compared with figures from 2007 (21.1 and 20.2%), as did the delivery rate per thawing for FER (13.7% in 2008 versus 13.5% in 2007) .
In comparison with the situation in Europe, data from other registers show that SET was performed in 63.9% of cycles in Australia and New Zealand (AIHW, 2010), and in 11.9% in the USA (CDC, 2010) . The delivery rates in Europe remain lower than in the USA where in fresh non-donor cycles performed in 2008 the delivery rate per aspiration was 33.8% (34.2% in IVF and 33.6% in ICSI) and the delivery rate per transfer was 36.7% (CDC, 2010) . However, the delivery rates in Europe were similar to those achieved in Australia and New Zealand, where the delivery rates in fresh cycles were 23.9% per transfer and 19.8% per aspiration (AIHW, 2010). The multiple-infant births (twins, triplets or more) were 31.6% in the USA and 8.4% in Australia and New Zealand.
Data on deliveries and babies must be considered and compared with some caution because of the difficulties met by several European countries in gathering pregnancy outcome (Supplementary data, Tables SXII and SXIII) while the pregnancy loss to follow-up was close to 0% both in the USA and Australia/New Zealand annual reports.
With the noticeable decline in the number of embryos transferred, the cumulative delivery rate per started cycle may be a most relevant endpoint for ART. However, this figure can only be obtained a few years after the initial oocyte aspiration. In Supplementary data, Table SXVIII, the cumulative delivery rate is presented as the sum of fresh and FER pregnancies obtained in the same calendar year. The method of calculation can be methodologically flawed but the estimate may be close to the actual figure. In several countries, FER deliveries added substantially to the delivery rates per cycle: Finland (19.8% to 30.5%), Belgium (17.0% to 22.6%), Sweden (21.7% to 29.4%) and Norway (23.4% to 29.5%), justifying their transfer and freezing policies.
PGD/PGS activity was recorded from 16 countries, and included 2875 cycles resulting in 411 deliveries (15.3% per aspiration). More complete data and detailed analysis of PGD/PGS in Europe will be published separately by ESHRE's PGD Consortium (Harper et al., 2010) .
Regarding direct risks of ART, OHSS was recorded in 1.0% of all stimulated cycles, at the same level as in 2006 (0.8%). However, there may be a degree of under-reporting, since the rate varied between 0.02% and 2.2% in the countries reporting it.
For the seventh consecutive year the present report includes European data on treatments with IUI-H (144 509 cycles) and IUI-D (24 960 cycles), thus showing an increase in IUI-H and a decrease in IUI-D, compared with 2007. Since data on IUI have been collected, no differences over time were noted in the delivery rate and in the incidence of multiple pregnancies.
In 2008, the EIM Consortium decided to also address the phenomenon of cross-border reproductive care (CBRC). An optional module was added to the data collection sheets asking for the numbers of CBRC patients, type of treatment requested, main countries of origin and the reason for travelling abroad. A total of 2514 cycles were reported by seven countries. The number was much lower than the estimated, based on the CBRC study performed recently in Europe (Shenfield et al., 2010) : 11 000 to 14 000 patients and 25 000 to 30 000 cycles per year. In addition, only incomplete information was reported regarding the countries of origin and reasons for travelling. Starting to collect new data is always difficult. However, because the CBRC phenomenon raises important public health concerns and underlines the need for a detailed evaluation, the Consortium will continue to gather more informative data in coming years.
In summary, the 12th ESHRE report on ART for Europe shows a continuing expansion in the numbers of participating clinics, countries and treatment cycles, with more than half a million cycles reported in 2008. The rise in the use of ICSI continued, reaching 69.0% in 2008. The delivery rates after IVF and ICSI remained relatively stable compared with 2007. The number of multiple transfers (3+ embryos) and the multiple delivery rate showed a marginal decline.
